Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Firmagon (Degarelix) Intermittent Therapy (FIT)

This study has been terminated.
(acrrual target was not being met)
Sponsor:
Collaborator:
Ferring Pharmaceuticals
Information provided by (Responsible Party):
Canadian Urology Research Consortium
ClinicalTrials.gov Identifier:
NCT01512472
First received: November 10, 2011
Last updated: October 13, 2016
Last verified: November 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: December 2017
  Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)